Galmed Pharmaceuticals Statistics
Total Valuation
GLMD has a market cap or net worth of $3.42 million. The enterprise value is -$14.60 million.
Important Dates
The next estimated earnings date is Thursday, May 21, 2026, before market open.
| Earnings Date | May 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GLMD has 6.58 million shares outstanding. The number of shares has increased by 363.17% in one year.
| Current Share Class | 6.58M |
| Shares Outstanding | 6.58M |
| Shares Change (YoY) | +363.17% |
| Shares Change (QoQ) | +10.16% |
| Owned by Insiders (%) | 3.08% |
| Owned by Institutions (%) | 6.03% |
| Float | 6.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.23 |
| P/TBV Ratio | 0.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.55
| Current Ratio | 6.55 |
| Quick Ratio | 6.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -107.72 |
Financial Efficiency
Return on equity (ROE) is -64.21% and return on invested capital (ROIC) is -33.13%.
| Return on Equity (ROE) | -64.21% |
| Return on Assets (ROA) | -28.65% |
| Return on Invested Capital (ROIC) | -33.13% |
| Return on Capital Employed (ROCE) | -53.92% |
| Weighted Average Cost of Capital (WACC) | 6.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.99% in the last 52 weeks. The beta is 0.47, so GLMD's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -58.99% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 44.10 |
| Average Volume (20 Days) | 21,692 |
Short Selling Information
The latest short interest is 17,367, so 0.27% of the outstanding shares have been sold short.
| Short Interest | 17,367 |
| Short Previous Month | 26,832 |
| Short % of Shares Out | 0.27% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.51M |
| Pretax Income | -10.31M |
| Net Income | -10.31M |
| EBITDA | -8.43M |
| EBIT | -8.51M |
| Earnings Per Share (EPS) | -$2.39 |
Full Income StatementBalance Sheet
The company has $18.16 million in cash and n/a in debt, with a net cash position of $18.16 million or $2.76 per share.
| Cash & Cash Equivalents | 18.16M |
| Total Debt | n/a |
| Net Cash | 18.16M |
| Net Cash Per Share | $2.76 |
| Equity (Book Value) | 15.78M |
| Book Value Per Share | 2.40 |
| Working Capital | 15.78M |
Full Balance SheetCash Flow
| Operating Cash Flow | -6.32M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 83,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -6.32M |
| FCF Per Share | -$0.96 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
